In a report issued on September 20, Liisa Bayko from JMP Securities reiterated a Hold rating on Summit Therapeutics (NASDAQ: SMMT). The company’s shares closed on Friday at $2.28, close to its 52-week low of $1.94.
According to TipRanks.com, Bayko is a 5-star analyst with an average return of 23.9% and a 53.2% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, DBV Technologies SA – American, and Enanta Pharmaceuticals.
Currently, the analyst consensus on Summit Therapeutics is a Moderate Buy with an average price target of $3.33, representing a 46.1% upside. In a report issued on September 21, Oppenheimer also assigned a Hold rating to the stock.
.
See today’s analyst top recommended stocks >>
Based on Summit Therapeutics’ latest earnings release for the quarter ending July 31, the company reported a quarterly net profit of $35.46 million. In comparison, last year the company had a net profit of $14.1 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Summit Therapeutics Plc is a holding company, which engages in the discovery, development, and commercialization of novel medicines. It focuses on the genetic disease duchenne muscular dystrophy, and the infectious disease clostridium difficile infection.
